NDA 022562 · Recordati Rare
Carbaglu
Carglumic Acid · Oral · Carbamoyl Phosphate Synthetase 1 Activator
NovelPriority reviewOrphanLast checked: Nov 20, 2026Latest source record: Jan 19, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2010
Mar 18, 2010
Approved uses
3
Original approval plus efficacy supplements
Registered trials
6
2 Phase 3, 2 recruiting
FAERS reports
753
598 serious, 152 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jan 25, 2024.
1. INDICATIONS AND USAGE CARBAGLU is a carbamoyl phosphate synthetase 1 (CPS 1) activator indicated in pediatric and adult patients as: Adjunctive therapy to standard of care for the treatment of acute hyperammonemia due to N-acetylglutamate synthase (NAGS) deficiency. ( 1.1 ) Maintenance therapy for the treatment of chronic hyperammonemia due to NAGS deficiency. ( 1.1 ) Adjunctive therapy to standard of care for the treatment of acute hyperammonemia due to propionic acidemia (PA) or methylmalonic acidemia (MMA). ( 1.2 ) 1.1 Acute and Chronic Hyperammonemia due to N‑acetylglutamate Synthase (NAGS) Deficiency CARBAGLU is indicated in adult and pediatric patients as: Adjunctive therapy to standard of care for the treatment of acute hyperammonemia due to NAGS deficiency. Maintenance therapy for the treatment of chronic hyperammonemia due to NAGS deficiency. 1.2 Acute Hyperammonemia due to Propionic Acidemia (PA) or Methylmalonic Acidemia (MMA) CARBAGLU is indicated in adult and pediatric patients as adjunctive therapy to standard of care for the treatment of acute hyperammonemia due to PA or MMA.
Mechanism: Carglumic acid is a synthetic structural analogue of N-acetylglutamate (NAG) which is produced from glutamate and acetyl-CoA in a reaction catalyzed by N‑acetylglutamate synthase (NAGS), a mitochondrial liver enzyme. NAG acts as the essential allosteric activator of carbamoyl phosphate synthetase 1 (CPS 1), a mitochondrial liver enzyme which catalyzes the first reaction of the urea cycle. The urea cycle, whose role is the disposition of ammonia, includes a series of biochemical reactions in the liver resulting in the conversion of ammonia into urea, which is then excreted through the urine....
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jan 22, 2021 Supplement 8 · Efficacy · priority review OrphanLetterLabel
- Jan 22, 2021 Supplement 9 · Efficacy · priority review OrphanLetterLabel
- Mar 18, 2010 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanLabelReviewLetter
1 products under this application
- CARBAGLU · CARGLUMIC ACID 200MG · TABLET, FOR SUSPENSION, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Carglumic Acid" as an intervention, any sponsor and status, largest first.
- N-Carbamylglutamate (Carbaglu) In The Treatment Of HyperammonemiaPivotal-lookingStatus unknown
Mendel TuchmanAcademic, hospital or other
NCT00843921 · 52 participants · Start Aug 2008 · Primary completion Apr 25, 2018
Drug: N-carbamylglutamate · For: Inborn Errors of Metabolism
Sites: Washington D.C., District of Columbia
Mendel TuchmanAcademic, hospital or other
NCT01599286 · 35 participants · Start Sep 1, 2012 · Primary completion Apr 30, 2019
Drug: Carbaglu; Placebo · For: Propionic Acidemia, Type I and/or Type II; Methylmalonic Acidemia; Carbamoyl-Phosphate Synthase I Deficiency Disease and 1 more
Sites: Los Angeles, California; Palo Alto, California; Aurora, Colorado · 9 sites in all
- Carglumic Acid in Methylmalonic Acidemia and Propionic AcidemiaPivotal-lookingCompleted
King Abdullah International Medical Research CenterAcademic, hospital or other
NCT02426775 · 33 participants · Start Nov 2015 · Primary completion Mar 19, 2019
Drug: Carglumic Acid · For: Propionic Acidemia; Methylmalonic Acidemia
Sites: Riyadh, Saudi Arabia · 2 sites in all
National Taiwan University HospitalAcademic, hospital or other
NCT04284917 · 3 participants · Start Nov 28, 2019 · Primary completion Dec 31, 2024
Drug: Carglumic Acid (Carbaglu®) · For: Propionic Acidemia (PA) , Methylmalonic Acidemia (MMA)
Sites: Taipei, Taiwan
- Long-term Outcome of N-Carbamylglutamate Treatment in Propionic Acidemia and Methylmalonic AcidemiaTerminated
Mendel TuchmanAcademic, hospital or other
NCT01597440 · 1 participants · Start Sep 2012 · Primary completion Feb 2015
Drug: N-carbamylglutamate · For: Propionic Acidemia; Methylmalonic Acidemia
Sites: Los Angeles, California; Palo Alto, California; Aurora, Colorado · 7 sites in all
Children's Hospital of PhiladelphiaAcademic, hospital or other
NCT01341379 · 0 participants · Start Dec 2010 · Primary completion Aug 2012
Drug: N-carbamylglutamate · For: Urea Cycle Disorders, Inborn; Inborn Errors of Metabolism; Propionic Acidemia and 2 more
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- off label use153
- vomiting148
- ammonia increased92
- hyperammonaemia56
- hospitalisation51
- death48
- diarrhoea47
- pyrexia31
- metabolic disorder28
- condition aggravated27
- drug ineffective24
- seizure22
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2010 | 3 |
| 2011 | 1 |
| 2012 | 6 |
| 2013 | 4 |
| 2014 | 8 |
| 2015 | 13 |
| 2016 | 7 |
| 2017 | 49 |
| 2018 | 60 |
| 2019 | 99 |
| 2020 | 103 |
| 2021 | 52 |
| 2022 | 70 |
| 2023 | 86 |
| 2024 | 99 |
| 2025 | 55 |
| 2026 | 38 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Carbaglu (Carglumic Acid)
2024 spending
$10.8M
Beneficiaries
n/a
68 claims
Per beneficiary
n/a
$231.93 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $5,416,189 |
| 2021 | $5,843,074 |
| 2022 | $7,996,841 |
| 2023 | $8,691,231 |
| 2024 | $10,812,445 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Long-term effectiveness of carglumic acid in patients with propionic acidemia (PA) and methylmalonic acidemia (MMA): a randomized clinical trial.
Alfadhel M, Nashabat M, Saleh M, et al. · Orphanet J Rare Dis 2021 · Multicenter Study, Randomized Controlled Trial
- Presentation and management of N-acetylglutamate synthase deficiency: a review of the literature.
Kenneson A, Singh RH · Orphanet J Rare Dis 2020 · Research Support, Non-U.S. Gov't, Systematic Review
Sponsor: Recordati Rare
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.